McKesson logo

McKesson (MCK) Q2 2026 Earnings

MCK·Reported November 5, 2025·After market close

McKesson reported Q2 2026 revenue of $103.15B (+10.1% YoY), missed analyst consensus of $104.14B by $986.3M. Diluted EPS came in at $9.86 (+39.5% YoY), beat the $9.03 consensus by $0.83. McKesson reports across 4 business segments, led by U.S. Pharmaceutical, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).

Revenue
$103.15Bmissed by $986.3M
Consensus: $104.14B
Diluted EPS
$9.86beat by $0.83
Consensus: $9.03
SEC

SEC Filings

Earnings release8-K · 0000927653-25-000138
Quarterly report10-Q · 0000927653-25-000140

Financial Snapshot

Trailing eight quarters through Q2 2026

View all metrics

Revenue

View metric

Net Income

View metric

Q2 2026 Earnings FAQ

Common questions about McKesson's Q2 2026 earnings report.

McKesson (MCK) reported Q2 2026 earnings on November 5, 2025 after market close.

McKesson reported revenue of $103.15B and diluted EPS of $9.86 for Q2 2026.

Revenue missed the consensus estimate of $104.14B by $986.3M. EPS beat the consensus estimate of $9.03 by $0.83.

Compared to the same quarter a year prior, revenue grew 10.1% from $93.7B a year earlier and diluted EPS grew 39.5% from $7.07.

You can read the 8-K earnings release (0000927653-25-000138) and the 10-Q periodic report (0000927653-25-000140) directly on SEC EDGAR. The filing index links above go to sec.gov.